

Docket No.: 20555/1203432-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Cheryl Fitzer-Attas et al.

Application No.: 10/619,454

Confirmation No.: 7700

Examiner: S. H. Standley

Filed: July 16, 2003

Art Unit: 1649

For: **PEPTIDES**SCREENING

AND METHODS OF IMMUNOGENIC PEPTIDE

AGAINST ALZHEIMER'S

VACCINES DISEASE

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This responds to the Office Action dated March 22, 2006, which set forth a restriction requirement for the above-identified application. A request for an extension of time and a check for the required fee are enclosed to extend the response period to September 22, 2006.

In response to the restriction requirement set forth in the Office Action, Applicant elects examination of invention Group II, claims 37-56. In response to the Examiner's requirement to elect a "species" from among the subject matter claimed in claims 46-56 for examination on the merits should no generic claim be finally held to be allowable, Applicant elects the further step of assessing for lack of ability to induce T-cell responses (see claim 46). The "further step" recited in claim 46 may be practiced with any of the methods of claims 37-56. Accordingly, all of claims 37-56 are believed to read on the elected species.

The election of the Group II claims and the species election are made without traverse.

This application is believed to be in condition for allowance. A prompt and favorable action on the merits of the application is earnestly solicited.

Dated: September 22, 2006

Respectfully submitted,

Mitchell Bernstein

Registration No.: 46,550 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant